US3873467A - Hematologic reference control - Google Patents

Hematologic reference control Download PDF

Info

Publication number
US3873467A
US3873467A US438542A US43854274A US3873467A US 3873467 A US3873467 A US 3873467A US 438542 A US438542 A US 438542A US 43854274 A US43854274 A US 43854274A US 3873467 A US3873467 A US 3873467A
Authority
US
United States
Prior art keywords
cells
reference control
red blood
cell volume
fluid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US438542A
Inventor
Roger A Hunt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biochem Immunosystems US Inc
United Medical Laboratories Inc
Original Assignee
United Medical Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Medical Laboratories Inc filed Critical United Medical Laboratories Inc
Priority to US438542A priority Critical patent/US3873467A/en
Application granted granted Critical
Publication of US3873467A publication Critical patent/US3873467A/en
Assigned to BAKER INSTRUMENTS CORPORATION reassignment BAKER INSTRUMENTS CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: J.T. BAKER CHEMICAL COMPANY, A CORP. OF NJ
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
    • G01N2400/22Dextran
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00Reference solutions for assays of biological material
    • G01N2496/05Reference solutions for assays of biological material containing blood cells or plasma
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666Particle count or volume standard or control [e.g., platelet count standards, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664Blood serum or blood plasma standard or control
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497Preparation composition [e.g., lysing or precipitation, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331Preservative, buffer, anticoagulant or diluent

Definitions

  • ABSTRACT A hematologic reference control provided for laboratory use in the calibration and control of automated and manual hematologic analyses.
  • the reference control comprises a suspension of washed, stabilized human red blood cells in a nonproteinaceous aqueous suspension fluid that replaces the plasma in human blood. Stability in the reference control is attained by conditioning the cells by the inclusion in the aqueous suspension fluid of materials tending to make the cells assume a spherical shape without substantial change in the mean cell volume of the cells as well as imparting to the cells a resistance to the normal tendency of degrading with time.
  • the aqueous suspension fluid furthermore produces an environment for the cells inhibiting biological activity.
  • the fixed cells are resistant to a Changein cell volume, and to dissolution under the action of lysing agents producing lysing of the stabilized cells.
  • the fixed red blood cells in the referencecontrol substitute for the white cell population in human blood.
  • This invention concerns generally what is referred to herein as a hematologic reference control, such comprising a suspension of human red blood cells in an aqueous suspension fluid usable in a hematology laboratory in the obtaining of reference values in connection with assays performed on human blood using manual and automated procedures.
  • a hematologic reference control such comprising a suspension of human red blood cells in an aqueous suspension fluid usable in a hematology laboratory in the obtaining of reference values in connection with assays performed on human blood using manual and automated procedures.
  • the reference control also should resemble human blood, with respect to pertinent characteristics, such as coloring, specific gravity, potassium and sodium ion concentrations, pH, and the manner in which the constituents thereof remain in suspension.
  • a general object is to provide a reference control exhibiting a stability that substantially exceeds that of controls presently known.
  • Another object of the invention is to provide a reference control which, with respect to pertinent physical characteristics, has a close resemblance to human blood.
  • an object is to provide a reference control including a population of human red blood cells suspended in a suspension fluid, with the cells conditioned in their suspended state so as to be resistant to degradation.
  • the cells nevertheless do respond to traditional lysing agents, whereby the reference control may be used in a procedure which requires lysing of red blood cells.
  • Another object is to provide a reference control which includes a group of specially processed human red blood cells, referred to as fixed cells, incorporated into the reference control to substitute for the white blood cell population, unstable with time, normally found in human blood.
  • These specially processed cells by reason of a swollen condition produced therein, and by reason of a fixing of the cells in their swollen condition, possess a specific gravity significantly less than that of normal red blood cells and similar to that of white blood cells, and will remain in this condition with substantially no change during the life of the reference control.
  • the fixing of the cells furthermore makes them resistant to dissolution or degradation under the influence of the usual lysing agents used in hematologic test procedures.
  • the fixed cells in the reference control tend to remain in suspension in a manner similar to white cells of human blood. Since the fixed cells are of human origin, certain advantages result such as ease of clean up, not attained with the use of other materials such as synthetic particles for the replacement of the white cells in human blood.
  • the reference control of the instant invention may be readily formulated to provide reference values usable in making assays of normal human blood. Additionally, if desired, the formulation of the reference control may be such as to provide reference values for abnormal ranges of blood.
  • human red blood cells are initially washed with an aqueous washing fluid, for the purpose of washing the cells free of plasma, anticoagulant, white blood cells and other debris, and to initiate stabilization of the cells, in a manner more fully to be described.
  • the washed red blood cells are suspended in an aqueous suspension fluid, formulated to have many of the physical characteristics of human blood plasma.
  • the suspension fluid is free of protein, to inhibit such things as bacterial growth in the fluid and surface accumulation of protein, and free of materials which normally favor biological activity in the cells.
  • the suspension fluid further includes certain salts dissolved therein, serving to condition the cells, whereby the cells transform into substantially spherical bodies with somewhat toughened cellular membranes.
  • the cells maintain substantially their original mean cell volume.
  • the cells in this condition exhibit maximum stability over the life of the reference control.
  • there is included in the suspension fluid a minor amount of swollen, fixed red blood cells, these specially processed swollen red cells substituting for the white cell population found in the usual human blood.
  • the washing fluid which is used in the initial processing of the so-called stabilized cells of the reference control, in addition to cleansing the cells to rid them of traces of plasma, platelets and other debris, is effective to initiate stabilization of the cells by performing a number of different functions.
  • the washing fluid may include a sulfhydryl group reactant exemplified by iodoacetamide, in sufficient quantity to react with and thus deactivate the free sulfhydryl groups found on normal red blood cells, to inhibit glycolysis and to prevent such sulfliydryl groups from antagonizing merthiolate or other similar antiseptic included in the suspension fluid for the purpose of inhibiting bacterial or fungal growth.
  • the washing liquid may further include a small amount of aldehyde, for the purpose of toughening the cell membranes, and material or materials promoting clumping or aggregating of the cells whereby after washing their separation from the washing fluid is promoted.
  • Materials of this latter category comprise Dextran, and sodium bicarbonate.
  • An alkali tartrate may be included as a membrane strengthener.
  • a typical washing fluid may comprise the following materials, preferably in the ranges indicated, dissolved in deionized or distilled water:
  • Material Molarity -Continued Material Molarity salt (EDTA, sodium salt) 0.00040-0.00080 Glutaraldehyde O-0.00008 Deionized or distilled water to desired volume
  • Commercially available packed human red blood cells may be washed with the washing fluid indicated above, as by introducing the blood cells at room temperature into a separatory vessel containing the washing fluid, and then gently mixing to prepare a suspension with the cells dispersed throughout the fluid. About 1 liter of washing fluid may be used in the washing of a unit of packed cells containing about 330 ml of material. After the mixing, the mixture is allowed to rest, which causes the red cells to aggregate and to precipitate, with such promoted by the Dextran and so dium bicarbonate in the washing fluid.
  • the supernatant. containing white blood cells, platelets, plasma, unprecipitated red blood cells and other debris is syphoned off.
  • the washed cells are then collected in a receptacle by draining them from the vessel, preferably with discarding of the first cells drained and discarding of the cells forming the top surface region of the precipitated cells.
  • the suspension fluid which substitutes for plasma in natural blood is an artificial nonplasma-type fluid substantially free of chlorine ions.
  • the fluid is buffered, to maintain a pH relatively unaffected by the red cells introduced into the fluid, and is formulated to have bactericidal and fungicidal qualities, so that prolonged storage will not result in growth of contaminating organisms.
  • the suspension fluid also imparts a resistance to degradation to washed red blood cells introduced into the fluid. and is formulated to have certain characteristics resembling that of human plasma, such as specific gravity, pH, and potassium and sodium ion concentrations.
  • the suspension fluid further includes a material tending to make the washed red blood cells substantially spherical in shape, without substantially changing the mean cell volume of the cells. As so conditioned, the cells have a stabilized shape while possessing substantially the specific gravity of normal red blood cells.
  • a typical formulation for a suspension fluid as contemplated herein comprises the following dissolved in deionized or distilled water, preferably in the ranges indicated:
  • Material Molarity Dextran (molecular weight 10,000 to 50.000) 0.00075 -0.00225 Ethanol 1.60 l .95 Merthiolate 0.00020 0.00030 Tetracycline hydrochloride 0.00030 Tris Hydroxymcth 1-2 Aminocthanc sul onic Ethylene dinitrilo tetra acetic acid, dipotassium salt (EDTA. potassium salt) Ethylene dinitrilo tetra acetic acid, tetrasodium salt (EDTA.
  • the potassium ion concentration is preferably selected to be within the range of 3 to 6 milliequivalents per liter, and the sodium ion concentration between and milliequivalents per liter.
  • the Dextran in the above formulation imparts to the suspension fluid a specific gravity (1.01-1.03) approximating that of normal plasma.
  • an antiseptic is introduced and also a membrane-active com pound serving to strengthen the membranes of washed cells introduced into the fluid which stabilizes the cell.
  • the merthiolate and tetracycline hydrochloride are antibacterial and antifungal in activity.
  • the sodium tartrate imparts resistance to cell degradation.
  • the sodium and potassium salts of EDTA are chelating agents, and introduce strength to cell membranes.
  • the BES, TES and HEPES are introduced for buffering purposes.
  • Various ratios of the three compounds are used according to the pH desired, their pK points at 20C. being 7.15, 7.50 and 7.55, respectively.
  • Washed red blood cells when suspended in a suspension fluid of the type indicated above, while being stable and resistant to degradation of the type that would adversely affect the stability of the reference control for hematologic measurements, nevertheless are susceptible to lysing when subjected to the usual lysing agents employed in hematologic procedures, such agents usually containing saponin or membrane-active detergent compounds.
  • this invention contemplates a small fraction of so-called fixed red blood cells in the reference control which substitute for white cell population in the usual blood. These are processed by first treating them with a swelling fluid, to induce swelling of the cells to a significantly greater mean cell volume. The swelling, however, is not so great as to produce hemolyzing and bursting ofthe cells. The swollen cells are then treated with a fixing fluid, which in effect subjects the cells to a tanning operation. The cells when so fixed maintain their swollen condition, and are resistant to the usual lysing agents used in hematologic procedures.
  • SWELLlNG FLUlD A swelling fluid as contemplated herein may comprise the following, preferably in the ranges indicated, dissolved in deionized or distilled water.
  • the swelling fluid having a solute concentration which is reduced from the solute concentration within the cells themselves.
  • the sodium and potassium concentration in the swelling fluid may typically be in the range of 50 to 60 milliequivalents, with the concentration within a typical cell being in the neighborhood of 140 milliequivalents. With the concentration of water outside the cells being greater than the concentration inside the cells, there is a tendency for the water concentration to equilibrate, with water moving inside the cells to swell them.
  • the normal specific gravity ofa cell may be within the range of 1.10 to 1.12. With swelling to approximately 50 percent greater volume, the specific gravity is reduced, to be within the range of 1.06 to 1.08.
  • the pH of the fluid normally would be within the range of 7.0 to 9.0.
  • the presence of the sodium bicarbonate and Dextran is to promote aggregation of the swollen red cells, to promote their separation from the swelling fluid.
  • the iodoacetamide while not strictly necessary, is included to inhibit glycolysis and to inactivate sulfhydryl groups, and performs a function similar to the functioning discussed in connection with the washing fluid.
  • the potassium sodium tartrate is a membrane strengthening agent, and functions to inhibit bursting of the cells under swelling conditions.
  • FIXING FLUID Material Molarity Potassium sodium tartrate Glutaraldehyde Deionized or distilled water to desired volume It should be noted that there is a relatively high concentration of the aldehyde in the above formulation, such being the tanning agent.
  • the potassium sodium tartrate is preferably included, to maintain the swollen cells in their swollen condition during the tanning of the cells with the aldehyde.
  • a unit of packed human blood cells (about 330 ml) may be deposited in a separatory funnel and a liter of swelling fluid added thereto. With gentle swirling, a suspension is produced. During swirling, the cells swell to about 150 percent their original mean cell volume, the unit of blood thereby increasing to about 500 ml.
  • the swollen cells then may be permitted to settle or precipitate for 1 hour.
  • the swollen cells may be drained from the base of the funnel.
  • the first few milliliters of the packed cells drained are discarded as well as the cells making up the top layer in the separatory funnel in order to obtain a pure sample.
  • the swollen cells so produced may be introduced into 2 liters of fixing fluid which is being rapidly stirred. The rapid stirring is continued for a period of about 24 hours. The molarity of the glutaraldehyde is then approximately doubled from the molarity of the original fixing fluid, and stirring continued for another 24 hours. While this rapid stirring continues, some energy may be introduced at about watts/cm to physically clean the cells and destroy those of marginal stability.
  • the fixed cells produced are then gently centrifuged, and the supernatant discarded.
  • the swollen fixed cells may then be washed with deionized or distilled water, or a physiological salt solution if desired.
  • a suspension may then be prepared from the remaining clean, fixed cells through addition of some suspension fluid, which conveniently may be about twice the volume of the fixed cells.
  • a cell count of the fixed cells in the fixed cell suspension so produced may be performed by a counting device such as a Coulter Counter, 21 conventional commercially available automatic blood counter which counts cells electronically as such are caused to pass through an orifice in the machine.
  • a Coulter Counter Model S reference is made to the article of Pinkerton, et al., entitled An Assessment of the Coulter Counter Model S appearing in the Journal of Clinical Pathology 1970, 23, 68-76.
  • a typical fixed cell suspension prepared as described above had a cell count performed thereon using a Coulter Counter Model F, indicating a cell count of fixed red cells of 1.5 million per mm.
  • a voltage threshhold was used in the counter similar to the threshhold used when making white cell counts of normal blood.
  • V (WS/F-W), wherein V is the volume in mls of fixed cell suspension to be added, W is the desired white cell count in cells per mm, S is the volume in mls of suspension of washed unfixed red blood cells to receive V, and F is the fixed cell suspension count in cells per mm, it was determined that 4.2 mls of the fixed cell suspension should be introduced to one liter of washed unfixed red cell suspension to produce the reference control desired. The resulting reference control was allowed to stand for a period of 14 days, to permit the washed unfixed cells to become fully stabilized in the suspension.
  • a reference control so produced was used in obtaining reference values with a Coulter Counter Model S.
  • a red cell count was performed on a fraction of the reference control, yielding a count of 4.82 $0.10 million per mm.
  • a white blood cell count was performed on another fraction (with lysing of the red cells using cyanmethemoglobin solution) yielding a count of 5.9 times i 0.4 thousand cells per mm.
  • the hemoglobin concentration as measured by the machine yielded a value of 15.4 i 0.2 gms per 100 ml sample.
  • the mean cell volume as measured by the counter was 922 i 2.2 cubic microns.
  • the values indicated are the mean plus or minus twice the standard deviation from the mean.
  • the reference control as contemplated herein may be assigned a refrigerated lifetime of at least 60 days from date of assay, during which time the hematologic values obtainable therefrom are expected to remain stable. Usually, longer lifetimes are expected. At room termperatures, stability is good, with the shelf life of the control usually exceeding 1 week. The color of the reference control remains red until well after the expected life of the control, permitting its use as a quality control item.
  • the mean cell volume of the stabilized red cells of a typical reference control as measured directly or by calibrated automated devices stabilizes at about 90 cubic microns.
  • the specific gravity of the usual reference control for standard use is within the range of 1.045 and 1.070, and the pH between 7.0 and 7.5.
  • the potassium ion concentration of the usual control ranges from 3 to 6 milliequivalents per liter, and the sodium ion concentration between 120 and 160 milliequivalents per liter.
  • a hematologic reference control comprising a suspension of stabilized human red blood cells in a nonproteinaceous aqueous suspension fluid, said blood cells retaining ability to respond to a lysing agent by dissolution, and being conditioned in said suspension by the inclusion in said suspension fluid ofa disulfonic acid salt of naphthol, and an alkaline tartrate.
  • the reference control of claim 1 which further includes Dextran having a molecular weight within a range of 10,000 to 50,000 dissolved in said suspension fluid, and imparting to the suspension fluid a specific gravity within the range of 1.01 to 1.03.
  • the reference control of claim 1 which further includes a minor amount of fixed human red blood cells, swollen to significantly greater mean cell volume than the mean cell volume of the stabilized cells and functioning as a substitute for the white cell population in human blood, the fixed cells having been fixed through an aldehyde treatment so as to be resistant to a change in mean cell volume, and resistant to dissolution by a lysing agent producing dissolution of the stabilized cells.
  • the reference control of claim 1 which further includes Dextran having a molecular weight within a range of 10,000 to 50,000, which is dissolved in the suspension liquid and imparts to the suspension fluid a specific gravity within the range of 1.01 to 1.03, and a minor amount of fixed human red blood cells swollen to significantly greater mean cell volume than the mean cell volume of the stabilized red blood cells and functioning as a substitute for the white cell population in human blood, said fixed cells being fixed through an aldehyde treatment to be resistant to a change in mean cell volume and resistant to dissolution by a lysing agent producing dissolution of the stabilized cells.
  • a hematologic reference control including a first group of human red blood cells suspended in an aqueous suspension fluid, a second group of human red blood cells suspended in said suspension fluid functioning to substitute for the white cell population of human blood, said second group of red blood cells consisting of cells in a swollen state whereby the cells of the second group have a significantly greater mean cell volume than the mean cell volume of the cells in the first group, the cells of the second group having been fixed in their swollen state whereby said cells are more resistant to change in cell volume and to dissolution than the remainder of the cells.
  • a swelling fluid for the swelling of human red blood cells to increase their mean cell volume and to promote aggregation of the cells in their swollen state comprising an aqueous solution of sodium bicarbonate, iodoacetamide. an alkali tartrate, and Dextran having a molecular weight within a range of about 150,000 to 350,000.
  • a fixing fluid for fixing swollen human red blood cells in their swollen state and imparting resistance to dissolution by lysing agents, comprising an aqueous solution of an alkali tartrate and glutaraldehyde.

Abstract

A hematologic reference control provided for laboratory use in the calibration and control of automated and manual hematologic analyses. The reference control comprises a suspension of washed, stabilized human red blood cells in a nonproteinaceous aqueous suspension fluid that replaces the plasma in human blood. Stability in the reference control is attained by conditioning the cells by the inclusion in the aqueous suspension fluid of materials tending to make the cells assume a spherical shape without substantial change in the mean cell volume of the cells as well as imparting to the cells a resistance to the normal tendency of degrading with time. The aqueous suspension fluid furthermore produces an environment for the cells inhibiting biological activity. In a preferred embodiment there is further included in the reference control a minor amount of fixed human red blood cells, processed to have a substantially increased mean cell volume. The fixed cells are resistant to a change in cell volume, and to dissolution under the action of lysing agents producing lysing of the stabilized cells. The fixed red blood cells in the reference control substitute for the white cell population in human blood.

Description

United States Patent [191 Hunt [11] 3,873,467 Mar. 25, 1975 HEMATOLOGIC REFERENCE CONTROL [751 inventor: Roger A. Hunt, Woodland, Wash.
[73] Assignee: United Medical Laboratories, lnc., Portland, Oreg.
221 Filed: Feb. 1, 1974 [2l] Appl. No.: 438,542
Primary Examiner-R. E. Serwin Attorney, Agent, or FirmKolisch, Hartwell, Dickinson & Stuart [57] ABSTRACT A hematologic reference control provided for laboratory use in the calibration and control of automated and manual hematologic analyses. The reference control comprises a suspension of washed, stabilized human red blood cells in a nonproteinaceous aqueous suspension fluid that replaces the plasma in human blood. Stability in the reference control is attained by conditioning the cells by the inclusion in the aqueous suspension fluid of materials tending to make the cells assume a spherical shape without substantial change in the mean cell volume of the cells as well as imparting to the cells a resistance to the normal tendency of degrading with time. The aqueous suspension fluid furthermore produces an environment for the cells inhibiting biological activity. In a preferred embodiment there is further included in the reference control a minor amount of fixed human red blood cells, processed to have a substantially increased mean cell volume. The fixed cells are resistant to a Changein cell volume, and to dissolution under the action of lysing agents producing lysing of the stabilized cells. The fixed red blood cells in the referencecontrol substitute for the white cell population in human blood.
8 Claims, No Drawings 1 HEMATOLOGIC REFERENCE CONTROL This invention concerns generally what is referred to herein as a hematologic reference control, such comprising a suspension of human red blood cells in an aqueous suspension fluid usable in a hematology laboratory in the obtaining of reference values in connection with assays performed on human blood using manual and automated procedures.
A need exists for such a reference control which is stable, in that the same can be used over a long period of time without substantial change occurring in the reference values obtained therefrom. Preferably the reference control also should resemble human blood, with respect to pertinent characteristics, such as coloring, specific gravity, potassium and sodium ion concentrations, pH, and the manner in which the constituents thereof remain in suspension.
A general object, therefore, is to provide a reference control exhibiting a stability that substantially exceeds that of controls presently known.
Another object of the invention is to provide a reference control which, with respect to pertinent physical characteristics, has a close resemblance to human blood.
More specifically an object is to provide a reference control including a population of human red blood cells suspended in a suspension fluid, with the cells conditioned in their suspended state so as to be resistant to degradation. The cells nevertheless do respond to traditional lysing agents, whereby the reference control may be used in a procedure which requires lysing of red blood cells.
Another object is to provide a reference control which includes a group of specially processed human red blood cells, referred to as fixed cells, incorporated into the reference control to substitute for the white blood cell population, unstable with time, normally found in human blood. These specially processed cells, by reason of a swollen condition produced therein, and by reason of a fixing of the cells in their swollen condition, possess a specific gravity significantly less than that of normal red blood cells and similar to that of white blood cells, and will remain in this condition with substantially no change during the life of the reference control. The fixing of the cells furthermore makes them resistant to dissolution or degradation under the influence of the usual lysing agents used in hematologic test procedures. The fixed cells in the reference control tend to remain in suspension in a manner similar to white cells of human blood. Since the fixed cells are of human origin, certain advantages result such as ease of clean up, not attained with the use of other materials such as synthetic particles for the replacement of the white cells in human blood.
The reference control of the instant invention may be readily formulated to provide reference values usable in making assays of normal human blood. Additionally, if desired, the formulation of the reference control may be such as to provide reference values for abnormal ranges of blood.
The foregoing and other objects and advantages of the instant invention will become more fully apparent from a reading of the following description, to be taken in conjunction with the specific examples set forth included to illustrate the invention specifically.
Speaking in general terms, in a reference control according to a preferred embodiment of the instant invention, human red blood cells are initially washed with an aqueous washing fluid, for the purpose of washing the cells free of plasma, anticoagulant, white blood cells and other debris, and to initiate stabilization of the cells, in a manner more fully to be described. The washed red blood cells are suspended in an aqueous suspension fluid, formulated to have many of the physical characteristics of human blood plasma. The suspension fluid is free of protein, to inhibit such things as bacterial growth in the fluid and surface accumulation of protein, and free of materials which normally favor biological activity in the cells. The suspension fluid further includes certain salts dissolved therein, serving to condition the cells, whereby the cells transform into substantially spherical bodies with somewhat toughened cellular membranes. The cells, however, maintain substantially their original mean cell volume. The cells in this condition exhibit maximum stability over the life of the reference control. Finally, there is included in the suspension fluid a minor amount of swollen, fixed red blood cells, these specially processed swollen red cells substituting for the white cell population found in the usual human blood.
WASHING FLUID The washing fluid which is used in the initial processing of the so-called stabilized cells of the reference control, in addition to cleansing the cells to rid them of traces of plasma, platelets and other debris, is effective to initiate stabilization of the cells by performing a number of different functions. Thus, the washing fluid may include a sulfhydryl group reactant exemplified by iodoacetamide, in sufficient quantity to react with and thus deactivate the free sulfhydryl groups found on normal red blood cells, to inhibit glycolysis and to prevent such sulfliydryl groups from antagonizing merthiolate or other similar antiseptic included in the suspension fluid for the purpose of inhibiting bacterial or fungal growth. Stabilization of the cell membranes, and protection against hemolysis, is gained by the inclusion of an ethylene dinitrilo tetraacetic acid salt or salts, these functioning as a chelating material effective to remove multivalent positive ions from the cells, as exemplified by the calcium ion. The washing liquid may further include a small amount of aldehyde, for the purpose of toughening the cell membranes, and material or materials promoting clumping or aggregating of the cells whereby after washing their separation from the washing fluid is promoted. Materials of this latter category comprise Dextran, and sodium bicarbonate. An alkali tartrate may be included as a membrane strengthener. Thus, a typical washing fluid may comprise the following materials, preferably in the ranges indicated, dissolved in deionized or distilled water:
Material Molarity -Continued Material Molarity salt (EDTA, sodium salt) 0.00040-0.00080 Glutaraldehyde O-0.00008 Deionized or distilled water to desired volume Commercially available packed human red blood cells may be washed with the washing fluid indicated above, as by introducing the blood cells at room temperature into a separatory vessel containing the washing fluid, and then gently mixing to prepare a suspension with the cells dispersed throughout the fluid. About 1 liter of washing fluid may be used in the washing of a unit of packed cells containing about 330 ml of material. After the mixing, the mixture is allowed to rest, which causes the red cells to aggregate and to precipitate, with such promoted by the Dextran and so dium bicarbonate in the washing fluid. The supernatant. containing white blood cells, platelets, plasma, unprecipitated red blood cells and other debris is syphoned off. The washed cells are then collected in a receptacle by draining them from the vessel, preferably with discarding of the first cells drained and discarding of the cells forming the top surface region of the precipitated cells.
SUSPENSION FLUID The suspension fluid which substitutes for plasma in natural blood is an artificial nonplasma-type fluid substantially free of chlorine ions. The fluid is buffered, to maintain a pH relatively unaffected by the red cells introduced into the fluid, and is formulated to have bactericidal and fungicidal qualities, so that prolonged storage will not result in growth of contaminating organisms. The suspension fluid also imparts a resistance to degradation to washed red blood cells introduced into the fluid. and is formulated to have certain characteristics resembling that of human plasma, such as specific gravity, pH, and potassium and sodium ion concentrations.
The suspension fluid further includes a material tending to make the washed red blood cells substantially spherical in shape, without substantially changing the mean cell volume of the cells. As so conditioned, the cells have a stabilized shape while possessing substantially the specific gravity of normal red blood cells.
A typical formulation for a suspension fluid as contemplated herein comprises the following dissolved in deionized or distilled water, preferably in the ranges indicated:
Material Molarity Dextran (molecular weight 10,000 to 50.000) 0.00075 -0.00225 Ethanol 1.60 l .95 Merthiolate 0.00020 0.00030 Tetracycline hydrochloride 0.00030 Tris Hydroxymcth 1-2 Aminocthanc sul onic Ethylene dinitrilo tetra acetic acid, dipotassium salt (EDTA. potassium salt) Ethylene dinitrilo tetra acetic acid, tetrasodium salt (EDTA. sodium salt) Sodium hydroxide to pH of Deionized or distilled water to desired volume The potassium ion concentration is preferably selected to be within the range of 3 to 6 milliequivalents per liter, and the sodium ion concentration between and milliequivalents per liter. The Dextran in the above formulation imparts to the suspension fluid a specific gravity (1.01-1.03) approximating that of normal plasma. By the inclusion of the ethanol, an antiseptic is introduced and also a membrane-active com pound serving to strengthen the membranes of washed cells introduced into the fluid which stabilizes the cell. The merthiolate and tetracycline hydrochloride are antibacterial and antifungal in activity. The sodium tartrate imparts resistance to cell degradation. The sodium and potassium salts of EDTA are chelating agents, and introduce strength to cell membranes. The BES, TES and HEPES are introduced for buffering purposes. Various ratios of the three compounds are used according to the pH desired, their pK points at 20C. being 7.15, 7.50 and 7.55, respectively.
By the inclusion of the disulfonic acid salt of naphthol, it is observed that washed red blood cells suspended in the fluid tend to round out and assume spherical shapes, without a substantial change in mean cell volume. This spherical shape is stable and maintained over the life of the reference control.
Washed red blood cells, when suspended in a suspension fluid of the type indicated above, while being stable and resistant to degradation of the type that would adversely affect the stability of the reference control for hematologic measurements, nevertheless are susceptible to lysing when subjected to the usual lysing agents employed in hematologic procedures, such agents usually containing saponin or membrane-active detergent compounds.
As previously indicated, this invention contemplates a small fraction of so-called fixed red blood cells in the reference control which substitute for white cell population in the usual blood. These are processed by first treating them with a swelling fluid, to induce swelling of the cells to a significantly greater mean cell volume. The swelling, however, is not so great as to produce hemolyzing and bursting ofthe cells. The swollen cells are then treated with a fixing fluid, which in effect subjects the cells to a tanning operation. The cells when so fixed maintain their swollen condition, and are resistant to the usual lysing agents used in hematologic procedures.
SWELLlNG FLUlD A swelling fluid as contemplated herein may comprise the following, preferably in the ranges indicated, dissolved in deionized or distilled water.
Mate rial Molarity Swelling of the red blood cells when such are immersed in the swelling fluid is the result of osmosis, the swelling fluid having a solute concentration which is reduced from the solute concentration within the cells themselves. Thus, the sodium and potassium concentration in the swelling fluid may typically be in the range of 50 to 60 milliequivalents, with the concentration within a typical cell being in the neighborhood of 140 milliequivalents. With the concentration of water outside the cells being greater than the concentration inside the cells, there is a tendency for the water concentration to equilibrate, with water moving inside the cells to swell them. The normal specific gravity ofa cell may be within the range of 1.10 to 1.12. With swelling to approximately 50 percent greater volume, the specific gravity is reduced, to be within the range of 1.06 to 1.08.
Referring to the formulation for the swelling fluid set forth above, the pH of the fluid normally would be within the range of 7.0 to 9.0. The presence of the sodium bicarbonate and Dextran is to promote aggregation of the swollen red cells, to promote their separation from the swelling fluid. The iodoacetamide, while not strictly necessary, is included to inhibit glycolysis and to inactivate sulfhydryl groups, and performs a function similar to the functioning discussed in connection with the washing fluid. The potassium sodium tartrate is a membrane strengthening agent, and functions to inhibit bursting of the cells under swelling conditions.
FIXING FLUID Material Molarity Potassium sodium tartrate Glutaraldehyde Deionized or distilled water to desired volume It should be noted that there is a relatively high concentration of the aldehyde in the above formulation, such being the tanning agent. The potassium sodium tartrate is preferably included, to maintain the swollen cells in their swollen condition during the tanning of the cells with the aldehyde.
PRODUCTION OF ALDEHYDE FIXED RED BLOOD CELLS In preparing the fixed red blood cells, a unit of packed human blood cells (about 330 ml) may be deposited in a separatory funnel and a liter of swelling fluid added thereto. With gentle swirling, a suspension is produced. During swirling, the cells swell to about 150 percent their original mean cell volume, the unit of blood thereby increasing to about 500 ml.
The swollen cells then may be permitted to settle or precipitate for 1 hour. The swollen cells may be drained from the base of the funnel. Preferably, the first few milliliters of the packed cells drained are discarded as well as the cells making up the top layer in the separatory funnel in order to obtain a pure sample.
The swollen cells so produced may be introduced into 2 liters of fixing fluid which is being rapidly stirred. The rapid stirring is continued for a period of about 24 hours. The molarity of the glutaraldehyde is then approximately doubled from the molarity of the original fixing fluid, and stirring continued for another 24 hours. While this rapid stirring continues, some energy may be introduced at about watts/cm to physically clean the cells and destroy those of marginal stability. The fixed cells produced are then gently centrifuged, and the supernatant discarded. The swollen fixed cells may then be washed with deionized or distilled water, or a physiological salt solution if desired. A suspension may then be prepared from the remaining clean, fixed cells through addition of some suspension fluid, which conveniently may be about twice the volume of the fixed cells. A cell count of the fixed cells in the fixed cell suspension so produced may be performed by a counting device such as a Coulter Counter, 21 conventional commercially available automatic blood counter which counts cells electronically as such are caused to pass through an orifice in the machine. For a discussion ofa Coulter Counter Model S, reference is made to the article of Pinkerton, et al., entitled An Assessment of the Coulter Counter Model S appearing in the Journal of Clinical Pathology 1970, 23, 68-76.
PREPARATION OF REFERENCE CONTROL Describing the preparing of a typical reference control, and one usable to provide reference values generally paralleling those found in normal blood specimens, a measured volume of washed, unfixed, red blood cells prepared as described above was gently mixed with suspension fluid also prepared as described above, to produce a suspension of the washed, unfixed, red blood cells. The volume of suspension fluid added was 0.7 times the volume of the washed red blood cells, since this results in a red blood cell concentration in the final control approximating that of normal blood.
A typical fixed cell suspension prepared as described above had a cell count performed thereon using a Coulter Counter Model F, indicating a cell count of fixed red cells of 1.5 million per mm. In making the cell count, a voltage threshhold was used in the counter similar to the threshhold used when making white cell counts of normal blood.
Employing the formula V=(WS/F-W), wherein V is the volume in mls of fixed cell suspension to be added, W is the desired white cell count in cells per mm, S is the volume in mls of suspension of washed unfixed red blood cells to receive V, and F is the fixed cell suspension count in cells per mm, it was determined that 4.2 mls of the fixed cell suspension should be introduced to one liter of washed unfixed red cell suspension to produce the reference control desired. The resulting reference control was allowed to stand for a period of 14 days, to permit the washed unfixed cells to become fully stabilized in the suspension.
A reference control so produced was used in obtaining reference values with a Coulter Counter Model S. Thus, and following typical procedures with such a counter, a red cell count was performed on a fraction of the reference control, yielding a count of 4.82 $0.10 million per mm. A white blood cell count was performed on another fraction (with lysing of the red cells using cyanmethemoglobin solution) yielding a count of 5.9 times i 0.4 thousand cells per mm. The hemoglobin concentration as measured by the machine yielded a value of 15.4 i 0.2 gms per 100 ml sample. The mean cell volume as measured by the counter was 922 i 2.2 cubic microns. The values indicated are the mean plus or minus twice the standard deviation from the mean. The values indicated, which are typical of normal blood, held constant for more than 60 days after first assay. The values obtained were confirmed using known manual techniques.
Typically, the reference control as contemplated herein may be assigned a refrigerated lifetime of at least 60 days from date of assay, during which time the hematologic values obtainable therefrom are expected to remain stable. Usually, longer lifetimes are expected. At room termperatures, stability is good, with the shelf life of the control usually exceeding 1 week. The color of the reference control remains red until well after the expected life of the control, permitting its use as a quality control item. The mean cell volume of the stabilized red cells of a typical reference control as measured directly or by calibrated automated devices stabilizes at about 90 cubic microns. The specific gravity of the usual reference control for standard use is within the range of 1.045 and 1.070, and the pH between 7.0 and 7.5. The potassium ion concentration of the usual control ranges from 3 to 6 milliequivalents per liter, and the sodium ion concentration between 120 and 160 milliequivalents per liter.
It is claimed and desired to secure by Letters Patent:
1. A hematologic reference control comprising a suspension of stabilized human red blood cells in a nonproteinaceous aqueous suspension fluid, said blood cells retaining ability to respond to a lysing agent by dissolution, and being conditioned in said suspension by the inclusion in said suspension fluid ofa disulfonic acid salt of naphthol, and an alkaline tartrate.
2. The reference control of claim 1, which further includes Dextran having a molecular weight within a range of 10,000 to 50,000 dissolved in said suspension fluid, and imparting to the suspension fluid a specific gravity within the range of 1.01 to 1.03.
3. The reference control of claim 1, which further includes a minor amount of fixed human red blood cells, swollen to significantly greater mean cell volume than the mean cell volume of the stabilized cells and functioning as a substitute for the white cell population in human blood, the fixed cells having been fixed through an aldehyde treatment so as to be resistant to a change in mean cell volume, and resistant to dissolution by a lysing agent producing dissolution of the stabilized cells.
4. The reference control of claim 1, which further includes Dextran having a molecular weight within a range of 10,000 to 50,000, which is dissolved in the suspension liquid and imparts to the suspension fluid a specific gravity within the range of 1.01 to 1.03, and a minor amount of fixed human red blood cells swollen to significantly greater mean cell volume than the mean cell volume of the stabilized red blood cells and functioning as a substitute for the white cell population in human blood, said fixed cells being fixed through an aldehyde treatment to be resistant to a change in mean cell volume and resistant to dissolution by a lysing agent producing dissolution of the stabilized cells.
5. In a hematologic reference control including a first group of human red blood cells suspended in an aqueous suspension fluid, a second group of human red blood cells suspended in said suspension fluid functioning to substitute for the white cell population of human blood, said second group of red blood cells consisting of cells in a swollen state whereby the cells of the second group have a significantly greater mean cell volume than the mean cell volume of the cells in the first group, the cells of the second group having been fixed in their swollen state whereby said cells are more resistant to change in cell volume and to dissolution than the remainder of the cells.
6. The reference control of claim 5, wherein fixing of the cells of said second group is by submersing the cells in an aldehyde tanning solution.
7. A swelling fluid for the swelling of human red blood cells to increase their mean cell volume and to promote aggregation of the cells in their swollen state comprising an aqueous solution of sodium bicarbonate, iodoacetamide. an alkali tartrate, and Dextran having a molecular weight within a range of about 150,000 to 350,000.
8. A fixing fluid, for fixing swollen human red blood cells in their swollen state and imparting resistance to dissolution by lysing agents, comprising an aqueous solution of an alkali tartrate and glutaraldehyde.

Claims (8)

1. A HEMATOLOGIC REFERENCE CONTROL COMPRISING A SUSPENSION OF STABILIZED HUMAN RED BLOOD CELLS IN A NONPROTEINACEOUS AQUEOUS SUSPENSION FLUID, SAID BLOOD CELLS RETAINING ABILITY TO RESPOND TO A LYSING AGENT BY DISSOLUTION, AND BEING CONDITIONED IN SAID SUSPENSION BY THE INCLUSION, IN SAID SUSPENSION FLUID OF A DISULFONIC ACID SALT OF NAPHTHOL, AND AN ALKALINE TARTRATE.
2. The reference control of claim 1, which further includes Dextran having a molecular weight within a range of 10,000 to 50, 000 dissolved in said suspension fluid, and imparting to the suspension fluid a specific gravity within the range of 1.01 to 1.03.
3. The reference control of claim 1, which further includes a minor amount of fixed human red blood cells, swollen to significantly greater mean cell volume than the mean cell volume of the stabilized cells and functioning as a substitute for the white cell population in human blood, the fixed cells having been fixed through an aldehyde treatment so as to be resistant to a change in mean cell volume, and resistant to dissolution by a lysing agent producing dissolution of the stabilized cells.
4. The reference control of claim 1, which further includes Dextran having a molecular weight within a range of 10,000 to 50, 000, which is dissolved in the suspension liquid and imparts to the suspension fluid a specific gravity within the range of 1.01 to 1.03, and a minor amount of fixed human red blood cells swollen to significantly greater mean cell volume than the mean cell volume of the stabilized red blood cells and functioning as a substitute for the white cell population in human blood, said fixed cells being fixed through an aldehyde treatment to be resistant to a change in mean cell volume and resistant to dissolution by a lysing agent producing dissolution of the stabilized cells.
5. In a hematologic reference control including a first group of human red blood cells suspended in an aqueous suspension fluid, a second group of human red blood cells suspended in said suspension fluid functioning to substitute for the white cell population of human blood, said second group of red blood cells consisting of cells in a swollen state whereby the cells of the second group have a significantly greater mean cell volume than the mean cell volume of the cells in the first group, the cells of the second group having been fixed in their swollen state whereby said cells are more resistant to change in cell volume and to dissolution than the remainder of the cells.
6. The reference control of claim 5, wherein fixing of the cells of said second group is by submersing the cells in an aldehyde tanning solution.
7. A swelling fluid for the swelling of human red blood cells to increase their mean cell volume and to promote aggregation of the cells in their swollen state comprising an aqueous solution of sodium bicarbonate, iodoacetamide, an alkali tartrate, and Dextran having a molecular weight within a range of about 150,000 to 350,000.
8. A fixing fluid, for fixing swollen human red blood cells in their swollen state and imparting resistance to dissolution by lysing agents, comprising an aqueous solution of an alkali tartrate and glutaraldehyde.
US438542A 1974-02-01 1974-02-01 Hematologic reference control Expired - Lifetime US3873467A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US438542A US3873467A (en) 1974-02-01 1974-02-01 Hematologic reference control

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US438542A US3873467A (en) 1974-02-01 1974-02-01 Hematologic reference control

Publications (1)

Publication Number Publication Date
US3873467A true US3873467A (en) 1975-03-25

Family

ID=23741019

Family Applications (1)

Application Number Title Priority Date Filing Date
US438542A Expired - Lifetime US3873467A (en) 1974-02-01 1974-02-01 Hematologic reference control

Country Status (1)

Country Link
US (1) US3873467A (en)

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3973913A (en) * 1976-01-29 1976-08-10 Louderback Allan Lee Blood control standard
US4007008A (en) * 1975-07-30 1977-02-08 Becker Milton J Preparation of reference serum from animal blood
US4054488A (en) * 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
US4081372A (en) * 1975-12-08 1978-03-28 University Of Utah Leakage indicator for recirculating peritoneal dialysis system
US4090977A (en) * 1976-11-22 1978-05-23 Research Corporation Osmotically balanced anticoaglant
US4102810A (en) * 1975-01-13 1978-07-25 Coulter Electronics, Inc. Stabilized hematological reagent solutions
US4160644A (en) * 1977-06-13 1979-07-10 Streck Laboratories, Inc. Platelet reference control and method of preparation
US4179398A (en) * 1977-03-21 1979-12-18 ICN Medical Laboratories, Inc. Platelet control composition
FR2432172A1 (en) * 1978-06-15 1980-02-22 Coulter Electronics HEMATOLOGY REFERENCE CONTROL REAGENT FOR MULTIPLE ANALYSIS
US4206077A (en) * 1977-10-07 1980-06-03 Djuro Rodjak Agent for facilitating the counting of thrombocytes in blood samples
US4213876A (en) * 1978-08-22 1980-07-22 Coulter Electronics, Inc. Multi-purpose blood diluent for use in electronic blood analysis instrumentation
US4219440A (en) * 1979-06-06 1980-08-26 Coulter Electronics, Inc. Multiple analysis hematology reference control reagent and method of making the same
DE3017152A1 (en) * 1979-05-07 1980-11-27 Coulter Electronics MEANS FOR THE PRODUCTION OF A BLOOD COMPARATIVE MONITORING, METHOD FOR THEIR PRODUCTION AND DISCHARGING THEREFOR
US4244837A (en) * 1979-12-03 1981-01-13 Coulter Electronics, Inc. Multi-purpose blood diluent for use in electronic blood analysis instrumentation
US4250051A (en) * 1978-12-26 1981-02-10 Coulter Electronics, Inc. Preservative for use in calibrator compositions for blood analysis
US4287087A (en) * 1977-02-25 1981-09-01 Research Triangle Institute Fixed-dried blood platelets
US4302355A (en) * 1977-08-01 1981-11-24 Warner-Lambert Company Platelet reference control
US4324687A (en) * 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
US4358394A (en) * 1979-05-07 1982-11-09 Coulter Electronics, Inc. Process for preparing whole blood reference controls having long term stability
WO1983002328A1 (en) * 1981-12-21 1983-07-07 American Hospital Supply Corp Fresh blood (unfixed) hematology control
US4405719A (en) * 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4412004A (en) * 1981-06-26 1983-10-25 Technicon Instruments Corporation Method for treating red blood cells to effect sphering and reagent therefor
US4455376A (en) * 1979-09-17 1984-06-19 R. J. Harvey Instrument Corp. Photometric methods for counting the particulate components of blood
US4473569A (en) * 1981-11-24 1984-09-25 Sullivan Donncha O Protective composition for users of cyanoacrylate adhesives
EP0154522A2 (en) * 1984-02-29 1985-09-11 TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) Method for sphering and fixing whole blood erythrocytes
US4544656A (en) * 1982-08-17 1985-10-01 Sullivan Donncha O Pharmaceutical composition and method of treating psoriasis
US4579824A (en) * 1983-05-18 1986-04-01 Louderback Allan Lee Hematology control
US4704364A (en) * 1984-05-18 1987-11-03 Coulter Electronics, Inc. Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
US4751179A (en) * 1984-05-31 1988-06-14 Coulter Electronics, Inc. Method and reagents for differential determination of four populations of leukocytes in blood
EP0296874A1 (en) * 1987-06-25 1988-12-28 Fisher Scientific Company Hematology control or calibrator with red cell components of enhanced stability
US5045472A (en) * 1981-06-26 1991-09-03 Technicon Instruments Corporation Reagent mixture and composition for treating red blood cells to effect sphering
WO1993017330A1 (en) * 1992-02-24 1993-09-02 Coulter Corporation Hematology control composition for leukocyte analogs; and methods for their preparation and use
WO1993017329A1 (en) * 1992-02-24 1993-09-02 Coulter Corporation Suspension media for hematological composition and method for its use
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
WO1997013146A1 (en) * 1995-10-04 1997-04-10 Hycor Biomedical, Inc. Blood control standard
US5811303A (en) * 1997-04-01 1998-09-22 Streck Laboratories, Inc. Quantitative buffy coat control composition
US5895760A (en) * 1997-02-04 1999-04-20 Hycor Biomedical, Inc. Erythrocyte sedimentation rate control
US5994139A (en) * 1998-04-07 1999-11-30 Coulter International Corp. Stable hematology control composition and method of use
US6124089A (en) * 1999-04-30 2000-09-26 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6146901A (en) * 1997-06-16 2000-11-14 Hematronix, Inc. Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition
US6159682A (en) * 1999-04-30 2000-12-12 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6200500B1 (en) 1999-08-20 2001-03-13 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6221668B1 (en) 1999-08-20 2001-04-24 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6362003B1 (en) * 1992-02-24 2002-03-26 Coulter Corporation Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof
US6509192B1 (en) 1992-02-24 2003-01-21 Coulter International Corp. Quality control method
US6531321B1 (en) 2000-09-15 2003-03-11 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6569682B2 (en) 2001-07-27 2003-05-27 Coulter International Corp. Hematology control product with increased closed vial stability
US6653137B2 (en) 2001-12-03 2003-11-25 Streck Laboratories Inc. Hematology reference control
US6653063B2 (en) 2000-06-12 2003-11-25 Hematronix, Inc. Hematology composition using preserved white blood cells in combination with source particles to simulate native white blood cells and method of making same
US6723563B2 (en) 2001-12-03 2004-04-20 Streck Laboratories Inc. Hematology reference control
US20050079623A1 (en) * 2003-10-12 2005-04-14 Beckman Coulter, Inc. Method of using a reference control composition for measurement of nucleated red blood cells
US20050136409A1 (en) * 2003-12-19 2005-06-23 Beckman Coulter, Inc. Hematology controls for reticulocytes and nucleated red blood cells
US20050227359A1 (en) * 2004-04-07 2005-10-13 Beckman Coulter, Inc. Reference control containing a nucleated red blood cell component
US20050255447A1 (en) * 2004-05-13 2005-11-17 Beckman Coulter, Inc. Hematology reference control containing an immature granulocyte component
US20070218558A1 (en) * 2006-03-16 2007-09-20 Beckman Coulter, Inc. Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells
US20080026468A1 (en) * 2006-07-17 2008-01-31 Bio-Rad Laboratories, Inc. Preparation of a red blood cell component for a hematology control
US20080113438A1 (en) * 2006-11-14 2008-05-15 Beckman Coulter, Inc. Hematology Linearity Control Composition, System and Method of Use
EP1980857A1 (en) 2007-04-13 2008-10-15 Streck Inc. Simulated blood components and methods
WO2010083130A1 (en) 2009-01-13 2010-07-22 Bio-Rad Laboratories, Inc. Simulation of normal fresh blood platelets
WO2012149211A1 (en) 2011-04-28 2012-11-01 Beckman Coulter, Inc. Hematology control compositions with extended stability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558522A (en) * 1969-03-05 1971-01-26 Baxter Laboratories Inc Hematology control standard comprising washed red blood cells and synthetic latex particles
US3574137A (en) * 1969-02-25 1971-04-06 Pfizer Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium
US3632735A (en) * 1970-03-11 1972-01-04 Pfizer & Co C Method of stabilizing fowl red blood cells for use in hematology control compositions
US3640896A (en) * 1970-04-13 1972-02-08 Pfizer Process for stabilizing fowl red blood cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574137A (en) * 1969-02-25 1971-04-06 Pfizer Multiple-analysis hematology control comprising human red blood cells and fowl red blood cells in an anticoagulant containing human serologically compatible plasma medium
US3558522A (en) * 1969-03-05 1971-01-26 Baxter Laboratories Inc Hematology control standard comprising washed red blood cells and synthetic latex particles
US3632735A (en) * 1970-03-11 1972-01-04 Pfizer & Co C Method of stabilizing fowl red blood cells for use in hematology control compositions
US3640896A (en) * 1970-04-13 1972-02-08 Pfizer Process for stabilizing fowl red blood cells

Cited By (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4102810A (en) * 1975-01-13 1978-07-25 Coulter Electronics, Inc. Stabilized hematological reagent solutions
US4007008A (en) * 1975-07-30 1977-02-08 Becker Milton J Preparation of reference serum from animal blood
US4054488A (en) * 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
US4081372A (en) * 1975-12-08 1978-03-28 University Of Utah Leakage indicator for recirculating peritoneal dialysis system
US3973913A (en) * 1976-01-29 1976-08-10 Louderback Allan Lee Blood control standard
US4090977A (en) * 1976-11-22 1978-05-23 Research Corporation Osmotically balanced anticoaglant
US4287087A (en) * 1977-02-25 1981-09-01 Research Triangle Institute Fixed-dried blood platelets
US4179398A (en) * 1977-03-21 1979-12-18 ICN Medical Laboratories, Inc. Platelet control composition
US4160644A (en) * 1977-06-13 1979-07-10 Streck Laboratories, Inc. Platelet reference control and method of preparation
US4302355A (en) * 1977-08-01 1981-11-24 Warner-Lambert Company Platelet reference control
US4206077A (en) * 1977-10-07 1980-06-03 Djuro Rodjak Agent for facilitating the counting of thrombocytes in blood samples
FR2432172A1 (en) * 1978-06-15 1980-02-22 Coulter Electronics HEMATOLOGY REFERENCE CONTROL REAGENT FOR MULTIPLE ANALYSIS
US4213876A (en) * 1978-08-22 1980-07-22 Coulter Electronics, Inc. Multi-purpose blood diluent for use in electronic blood analysis instrumentation
US4250051A (en) * 1978-12-26 1981-02-10 Coulter Electronics, Inc. Preservative for use in calibrator compositions for blood analysis
US4324687A (en) * 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
US4299726A (en) * 1979-05-07 1981-11-10 Coulter Electronics, Inc. Process for preparing whole blood reference controls having long term stability, preconditioning diluent and media therefor
DE3017152A1 (en) * 1979-05-07 1980-11-27 Coulter Electronics MEANS FOR THE PRODUCTION OF A BLOOD COMPARATIVE MONITORING, METHOD FOR THEIR PRODUCTION AND DISCHARGING THEREFOR
US4358394A (en) * 1979-05-07 1982-11-09 Coulter Electronics, Inc. Process for preparing whole blood reference controls having long term stability
US4219440A (en) * 1979-06-06 1980-08-26 Coulter Electronics, Inc. Multiple analysis hematology reference control reagent and method of making the same
US4455376A (en) * 1979-09-17 1984-06-19 R. J. Harvey Instrument Corp. Photometric methods for counting the particulate components of blood
US4244837A (en) * 1979-12-03 1981-01-13 Coulter Electronics, Inc. Multi-purpose blood diluent for use in electronic blood analysis instrumentation
US4405719A (en) * 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US5045472A (en) * 1981-06-26 1991-09-03 Technicon Instruments Corporation Reagent mixture and composition for treating red blood cells to effect sphering
US4412004A (en) * 1981-06-26 1983-10-25 Technicon Instruments Corporation Method for treating red blood cells to effect sphering and reagent therefor
US4473569A (en) * 1981-11-24 1984-09-25 Sullivan Donncha O Protective composition for users of cyanoacrylate adhesives
WO1983002328A1 (en) * 1981-12-21 1983-07-07 American Hospital Supply Corp Fresh blood (unfixed) hematology control
US4489162A (en) * 1981-12-21 1984-12-18 American Hospital Supply Corporation Fresh blood (unfixed) hematology control
US4544656A (en) * 1982-08-17 1985-10-01 Sullivan Donncha O Pharmaceutical composition and method of treating psoriasis
US4579824A (en) * 1983-05-18 1986-04-01 Louderback Allan Lee Hematology control
EP0154522A3 (en) * 1984-02-29 1988-11-02 Technicon Instruments Corporation Method for sphering and fixing whole blood erythrocytes
EP0154522A2 (en) * 1984-02-29 1985-09-11 TECHNICON INSTRUMENTS CORPORATION(a Delaware corporation) Method for sphering and fixing whole blood erythrocytes
US5380664A (en) * 1984-05-18 1995-01-10 Coulter Corporation Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
US4704364A (en) * 1984-05-18 1987-11-03 Coulter Electronics, Inc. Hematology control compositions for three populations of leukocytes; and methods for their preparation and use in whole blood control systems
US4751179A (en) * 1984-05-31 1988-06-14 Coulter Electronics, Inc. Method and reagents for differential determination of four populations of leukocytes in blood
EP0296874A1 (en) * 1987-06-25 1988-12-28 Fisher Scientific Company Hematology control or calibrator with red cell components of enhanced stability
US5981282A (en) * 1991-05-09 1999-11-09 Streck Laboratories, Inc. White blood cell hematology control
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
US5731205A (en) * 1991-05-09 1998-03-24 Streck Laboratories, Inc. White blood cell hematology control
US5672474A (en) * 1991-05-09 1997-09-30 Streck Laboratories, Inc. White blood cell hematology control
US5677145A (en) * 1991-05-09 1997-10-14 Streck Laboratories, Inc. White blood cell hematology control
US20050095719A1 (en) * 1992-02-24 2005-05-05 Young Carole J. Quality control method
WO1993017330A1 (en) * 1992-02-24 1993-09-02 Coulter Corporation Hematology control composition for leukocyte analogs; and methods for their preparation and use
US5529933A (en) * 1992-02-24 1996-06-25 Coulter Corporation Suspension media for hematological composition and method for its use
US5512485A (en) * 1992-02-24 1996-04-30 Coulter Corporation Hematology control composition including leukocyte analogs; and methods for their preparation and use
AU665413B2 (en) * 1992-02-24 1996-01-04 Coulter International Corporation Hematology control composition for leukocyte analogs; and methods for their preparation and use
US5320964A (en) * 1992-02-24 1994-06-14 Coulter Corporation Hematology control composition including leukocyte analogs; and methods for their preparation and use
US6509192B1 (en) 1992-02-24 2003-01-21 Coulter International Corp. Quality control method
US20050221496A1 (en) * 1992-02-24 2005-10-06 Young Carole J Quality control method
US20050048657A1 (en) * 1992-02-24 2005-03-03 Young Carole J. Method of using a hematology control product
US20050048656A1 (en) * 1992-02-24 2005-03-03 Young Carole J. Quality control method
WO1993017329A1 (en) * 1992-02-24 1993-09-02 Coulter Corporation Suspension media for hematological composition and method for its use
US6362003B1 (en) * 1992-02-24 2002-03-26 Coulter Corporation Hematological reference control composition containing leukocyte analogs, methods of making, and uses thereof
US20050221497A1 (en) * 1992-02-24 2005-10-06 Carole Young Quality control method
US20030092184A1 (en) * 1992-02-24 2003-05-15 Coulter International Corporation Quality control method
US6051433A (en) * 1995-10-04 2000-04-18 Streck Laboratories, Inc. Erythrocyte sedimentation rate control
US6331435B1 (en) 1995-10-04 2001-12-18 Streak Laboratories, Inc. Erythrocyte sedimentation rate control
WO1997013146A1 (en) * 1995-10-04 1997-04-10 Hycor Biomedical, Inc. Blood control standard
US5863799A (en) * 1995-10-04 1999-01-26 Hycor Biomedical, Inc. Erythrocyte sedimentation rate control
US5888822A (en) * 1995-10-04 1999-03-30 Hycor Biomedical Inc. Erythrocyte sedimentation rate control
US6017764A (en) * 1997-02-04 2000-01-25 Streck Laboratories, Inc. Erythrocyte sedimentation rate control
US6342391B1 (en) 1997-02-04 2002-01-29 Streck Laboratories, Inc. Erythrocyte sedimentation rate control
US5895760A (en) * 1997-02-04 1999-04-20 Hycor Biomedical, Inc. Erythrocyte sedimentation rate control
US5811303A (en) * 1997-04-01 1998-09-22 Streck Laboratories, Inc. Quantitative buffy coat control composition
US6146901A (en) * 1997-06-16 2000-11-14 Hematronix, Inc. Composition for manipulating optical and electrical properties of particles to achieve target values for such properties and methods for using the composition
US5994139A (en) * 1998-04-07 1999-11-30 Coulter International Corp. Stable hematology control composition and method of use
US6265148B1 (en) 1999-04-30 2001-07-24 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6124089A (en) * 1999-04-30 2000-09-26 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6159682A (en) * 1999-04-30 2000-12-12 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6200500B1 (en) 1999-08-20 2001-03-13 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6406915B2 (en) 1999-08-20 2002-06-18 Streck Laboratoreis, Inc. Hematology control and system for multi-parameter hematology measurements
US6403377B1 (en) 1999-08-20 2002-06-11 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6399388B1 (en) 1999-08-20 2002-06-04 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6221668B1 (en) 1999-08-20 2001-04-24 Streck Laboratories, Inc. Hematology control and system for multi-parameter hematology measurements
US6653063B2 (en) 2000-06-12 2003-11-25 Hematronix, Inc. Hematology composition using preserved white blood cells in combination with source particles to simulate native white blood cells and method of making same
US6531321B1 (en) 2000-09-15 2003-03-11 Streck Laboratories, Inc. Blood control and system for erythrocyte sedimentation measurement
US6569682B2 (en) 2001-07-27 2003-05-27 Coulter International Corp. Hematology control product with increased closed vial stability
US6653137B2 (en) 2001-12-03 2003-11-25 Streck Laboratories Inc. Hematology reference control
US6723563B2 (en) 2001-12-03 2004-04-20 Streck Laboratories Inc. Hematology reference control
US20050079623A1 (en) * 2003-10-12 2005-04-14 Beckman Coulter, Inc. Method of using a reference control composition for measurement of nucleated red blood cells
US7198953B2 (en) 2003-10-12 2007-04-03 Beckman Coulter, Inc. Method of using a reference control composition for measurement of nucleated red blood cells
US7195919B2 (en) 2003-12-19 2007-03-27 Beckman Coulter, Inc. Hematology controls for reticulocytes and nucleated red blood cells
US20050136409A1 (en) * 2003-12-19 2005-06-23 Beckman Coulter, Inc. Hematology controls for reticulocytes and nucleated red blood cells
US7285417B2 (en) 2004-04-07 2007-10-23 Beckman Coulter Inc. Reference control containing a nucleated red blood cell component
US20070072298A1 (en) * 2004-04-07 2007-03-29 Beckman Coulter, Inc. Reference Control Containing a Nucleated Red Blood Cell Component
US20050227359A1 (en) * 2004-04-07 2005-10-13 Beckman Coulter, Inc. Reference control containing a nucleated red blood cell component
US7135341B2 (en) 2004-04-07 2006-11-14 Beckman Coulter, Inc. Reference control containing a nucleated red blood cell component
US7393688B2 (en) 2004-05-13 2008-07-01 Beckman Coulter, Inc. Method of using a hematology reference control for measurement of immature granulocytes
US20070020611A1 (en) * 2004-05-13 2007-01-25 Beckman Coulter, Inc. Hematology reference control containing an immature granulocyte component
US7109036B2 (en) 2004-05-13 2006-09-19 Beckman Coulter, Inc. Hematology reference control containing an immature granulocyte component
US20050255447A1 (en) * 2004-05-13 2005-11-17 Beckman Coulter, Inc. Hematology reference control containing an immature granulocyte component
US20070218558A1 (en) * 2006-03-16 2007-09-20 Beckman Coulter, Inc. Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells
US7354767B2 (en) 2006-03-16 2008-04-08 Beckman Coulter, Inc. Reference control composition containing a nucleated red blood cell component made of non-nucleated blood cells
US20080026468A1 (en) * 2006-07-17 2008-01-31 Bio-Rad Laboratories, Inc. Preparation of a red blood cell component for a hematology control
US7482161B2 (en) * 2006-07-17 2009-01-27 Bio-Rad Laboratories, Inc. Preparation of a red blood cell component for a hematology control
WO2008061073A2 (en) 2006-11-14 2008-05-22 Beckman Coulter, Inc. Hematology linearity control composition system and method of use
US20080113438A1 (en) * 2006-11-14 2008-05-15 Beckman Coulter, Inc. Hematology Linearity Control Composition, System and Method of Use
US7754487B2 (en) * 2006-11-14 2010-07-13 Beckman Coulter, Inc. Hematology linearity control composition, system and method of use
EP1980857A1 (en) 2007-04-13 2008-10-15 Streck Inc. Simulated blood components and methods
US20080254543A1 (en) * 2007-04-13 2008-10-16 Streck, Inc. Simulated blood components and methods
US7618821B2 (en) 2007-04-13 2009-11-17 Streck, Inc. Simulated blood components and methods
US20100047905A1 (en) * 2007-04-13 2010-02-25 Streck, Inc. Simulated blood components and methods
WO2010083130A1 (en) 2009-01-13 2010-07-22 Bio-Rad Laboratories, Inc. Simulation of normal fresh blood platelets
WO2012149211A1 (en) 2011-04-28 2012-11-01 Beckman Coulter, Inc. Hematology control compositions with extended stability

Similar Documents

Publication Publication Date Title
US3873467A (en) Hematologic reference control
US4373027A (en) Microparticles, preparation thereof and applications thereof in biology, particularly in the culture of human diploid cells
Cornick et al. Lobster (Homarus americanus) hemocytes: Classification, differential counts, and associated agglutinin activity
US3558522A (en) Hematology control standard comprising washed red blood cells and synthetic latex particles
Heimer et al. Improved mountant for immunofluorescence preparations.
US4389490A (en) Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; and diluents thereof
Kane The mitotic apparatus: fine structure of the isolated unit
LAGUNOFF Vital staining of mast cells with ruthenium red
US4416813A (en) Artificial carrier for immobilization of biological proteins
Robertson et al. Studies on pneumococcus growth inhibition: ii. A method for demonstrating the growth-inhibitory and bactericidal action of normal serum-leucocyte mixtures.
US4379847A (en) Suspending medium for immunologic reactions
US3864478A (en) Storage-stable hemoglobin solutions and method for their preparation
Endean Studies of the blood and tests of some Australian ascidians. II. The test of Pyura stolonifera (Heller)
US5286829A (en) Biocompatible polymer material and a process for producing same
US6017764A (en) Erythrocyte sedimentation rate control
Rabinovitch et al. Phagocytosis of erythrocytes by Acanthamoeba sp
EP0049478B1 (en) Multi-purpose blood diluent
Swanton et al. Experiences with the Coulter counter in bacteriology
Payne et al. Immersion refractometry of some halophilic bacteria
Brower et al. The effects of applied electric fields on Micrasterias: II. the distributions of cytoplasmic and plasma membrane components
Hopkins The effects of certain physical and chemical factors on locomotion and others life‐processes in Amoeba proteus
Elblbesy et al. Effect of gelatin concentration on the characterizations and hemocompatibility of polyvinyl alcohol–gelatin hydrogel
Baker et al. Chemically induced fusion of fresh human erythrocytes
George The histology of the blood of Perophora viridis (Ascidian)
Clawson et al. Platelet interaction with bacteria. V. Ultrastructure of congenital afibrinogenemic platelets.

Legal Events

Date Code Title Description
AS Assignment

Owner name: BAKER INSTRUMENTS CORPORATION 100 CASCADE DRIVE, A

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:J.T. BAKER CHEMICAL COMPANY, A CORP. OF NJ;REEL/FRAME:004142/0945

Effective date: 19830413